New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (Obinutuzumab) for Primary Membranous Nephropathy (pMN). haga clic aquí for more information. Please visit our Patient Navigation tool for support.

RECURSOS

/

ENCUENTRA UN ESPECIALISTA

/

CONTACTO

Josué Tarnoff

Director ejecutivo

Josh Tarnoff joined NephCure as CEO in early 2018, fulfilling a long-held desire to more closely serve the rare disease patient community. He spent 34 years in the pharmaceutical and biotechnology community, moving new therapies closer to reality. Josh led a few companies in the latter half of his career including a clinical phase company studying nephrotic syndrome. He now enjoys his time engaging with various rare kidney disease stakeholders including patient organizations, clincians, regulators, researchers, and industry sponsors on key porgrams to help advance cures for rare kidney diseases.

Las conexiones personales con las familias de NephCure alimentan su pasión por lograr los objetivos de alto impacto de NephCure, y siempre agradece hablar directamente con nuestra comunidad. Josh también tiene conocimientos personales sobre la enfermedad renal crónica, ya que alguna vez fue paciente, probablemente como resultado de una mordedura de serpiente. Vive en Pensilvania, donde disfruta de viajar con mochila, al mismo tiempo que intenta evitar un mayor contacto con serpientes venenosas.

Rey de Prusia, Pensilvania

Noticias relacionadas

NOTICIAS

The FDA Grants Accelerated Approval of ULTOMIRIS (ravulizumab-cwvz) for Adults with IgA Nephropathy 

NOTICIAS

NephCure Applauds U.S. Department of Health and Human Services on the Release of the Rare Kidney Disease Inclusive Kidney Care National Plan

NOTICIAS

NephCure Celebrates C3G Awareness Day on September 25, 2026

NOTICIAS

NephCure Specialist of the Month: Dr. Rupali Avasare

Regístrese para recibir las últimas actualizaciones de NephCure.

INSCRIBIRSE
Este campo es para fines de validación y no debe modificarse.